1D09C3, an mAb specific for MHC-II

Heddy Zola1, Alice Beare

  • 1Women's and Children's Health Research Institute, 72 King William Road, North Adelaide, SA 5006, South Australia. heddy.zola@adelaide.edu.au

Current Opinion in Molecular Therapeutics
|January 30, 2008
PubMed

GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.